Tc-99m-Tilmanocept Imaging for Diabetic Kidney Disease
Trial Summary
What is the purpose of this trial?
This proposal will use kidney SPECT/CT of Tc-99m-tilmanocept to evaluate the mesangial changes seen in diabetics across the spectrum of kidney disease as well as persons with hypertensive kidney disease, the next most common cause of kidney disease in patients with diabetes. We aim to demonstrate that these different disease types and stages can be differentiated with Tc-99m-tilmanocept SPECT/CT and can thus be used for future trials evaluating early diagnosis and treatment of diabetic nephropathy.
Research Team
Carl Hoh, MD
Principal Investigator
UC San Diego Medical Center
Eligibility Criteria
Adults over 18 with kidney disease, specifically diabetic or hypertensive kidney disease, can join this trial. They must consent to the study and not be pregnant or trying to conceive. Participants should have a stable health status (ECOG Grade 0-2) and a BMI between 18-49.9 kg/m2. Exclusions include recent drug/alcohol abuse, high radiation exposure, participation in other trials within 3 months, significant allergies to dextran, certain medication use prior to the trial start date, poor vein access for injections.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline and Treatment
Participants receive IV administration of Tc-99m-tilmanocept and undergo imaging procedures
Immediate Follow-up
Participants are monitored for adverse events and undergo additional imaging and laboratory evaluations
Safety Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Tc-99m-Tilmanocept
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor